Study summary

A four-week, randomized, double-blind, placebo-controlled trial in 74 healthy adults found that 3.5 g of Solnul® daily increased the relative abundance of Bifidobacterium and Akkermansia and increased the number of normal stools compared with placebo.ⁱ Participants taking Solnul® also experienced an increase in bowel movement frequency and a greater reduction in days without a bowel movement, with no effect on gastrointestinal symptoms. These findings reinforce Solnul® as a prebiotic and reproduce key microbiome outcomes, stool form benefits, and tolerability observed in the earlier study.

Read the full study in Nutrients ↗

ⁱ Bush, J. R., Iwuamadi, I., & Deehan, E. C. (2026). Examining the Gastrointestinal Effects of Solnul®, a Prebiotic Resistant Potato Starch: A Replication Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Healthy Adults. Nutrients, 18(21), 3538. https://doi.org/10.3390/nu18213538

Graphical abstract

Published graphical abstract of the Solnul replication clinical trial
Published graphical abstract. Click to view full size.

Source: Bush, J. R.; Iwuamadi, I.; Deehan, E. C. Nutrients 2026, 18(21), 3538. doi:10.3390/nu18213538. Trial registration: NCT06949631.

Summary adapted from the published abstract. Graphical abstract reproduced unchanged. © 2026 the authors. CC BY 4.0.